Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Sean Dwyer

Cardiovascular Disease Chevy Chase, MD Medical Doctor

NPI 1346248044 CMS profile 288211

5454 Wisconsin Ave, Suite 925, Chevy Chase, MD 20815

Open in the dashboard

General payments

$5,168

225 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Sean Dwyer of Chevy Chase, MD is reported in the CMS Open Payments database as having received $5,168 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $175 2
2022 General $616 31
2021 General $1,421 62
2020 General $787 41
2019 General $2,169 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Dwyer
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Sean Dwyer were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Sean Dwyer Cardiovascular Disease median Middle half National median
2019 $2,169 $450 $127–$1,392 $163
2020 $787 $242 $77–$751 $114
2021 $1,421 $335 $101–$1,037 $132
2022 $616 $395 $121–$1,211 $149
2023 $175 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amgen Inc. $886 32 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $464 19 payments
  3. Pfizer Inc. $446 23 payments
  4. E.R. Squibb & Sons, L.L.C. $443 16 payments
  5. Novartis Pharmaceuticals Corporation $348 18 payments
  6. Janssen Pharmaceuticals, Inc $327 14 payments
  7. Amarin Pharma Inc. $293 17 payments
  8. Esperion Therapeutics, Inc. $289 10 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $220 10 payments
  10. Sanofi-Aventis U.S. LLC $191 13 payments
  11. Other $1,260 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,147 223 payments
  2. Education $21 2 payments
Products named General payments · program years 2019–2023
  1. Repatha $886 32 payments
  2. JARDIANCE $464 19 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $391 20 payments
  4. Corlanor $390 18 payments
  5. XARELTO $327 14 payments
  6. NEXLETOL $289 10 payments
  7. ENTRESTO $286 15 payments
  8. Verquvo $220 10 payments
  9. Vascepa $216 13 payments
  10. ELIQUIS Cardiovascular $193 14 payments
  11. Other $2,299 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

375

Median for Internal Medicine: 777

Drug cost

$57,728

Median for Internal Medicine: $73,373

Branded share of claims

23.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 50 $53,233
Metoprolol Succinate Generic 68 $953
Ezetimibe Generic 32 $568
Lisinopril Generic 26 $501
Losartan Potassium Generic 20 $447
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 26 $373
Rosuvastatin Calcium Generic 17 $322
Amlodipine Besylate Generic 37 $319
Atorvastatin Calcium Generic 22 $255
Torsemide Generic 13 $186

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$13,288

Medicare's payments for the services billed

Medicare patients

203

Average age 77

Services billed

473

106 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 46%
Atrial fibrillation 45%
Arthritis 42%
COPD 32%
Heart failure 30%
Chronic kidney disease 28%
Diabetes 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record